Improvement of blood glucose levels and obesity in mice given aronia juice by inhibition of dipeptidyl peptidase IV and α-glucosidase

Yamane, Toshimi; Kozuka, Miyuki; Konda, Daisuke; Nakano, Yoshihisa; Nakagaki, Takenori; Ohkubo, Iwao; Ariga, Hiroyoshi

doi:10.1016/j.jnutbio.2016.02.004

Cited by 44 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are a few discrepancies in the articles related to the review in terms of the population being studied, duration of administration of Aronia, and mode of administration. Although there is promising antecedence for the provenance of Aronia in improving blood lipid profiles in a few animal studies (Jurgoński, Juśkiewicz, & Zduńczyk, ; Valcheva‐Kuzmanova, Kuzmanov, Tancheva, & Belcheva, ; Yamane et al, ), when performing this meta‐analysis, on the whole, we were unable to support such assertions, with meaningful improvements only noted in a few markers. Given the lack of consensus provided for certain variables, it is strongly recommended that studies with suitably powered sample sizes, and high‐quality RCTs, would enable equivocality to be ameliorated.…”

Section: Discussionmentioning

confidence: 68%

“…The crux of the purported health benefits of Aronia berry supplementation relates to the abundant concentrations of polyphenols, anthocyanins, hydroxycinnamic acids, and proanthocyanidins presented within it. Aronia berry has been reported to play a role in the control of hyperglycemia and, invariably, positively influencing blood pressure (Banjari et al, ; Valcheva‐Kuzmanova, Kuzmanov, Tancheva, & Belcheva, ; Yamane et al, ). Therefore, the aim of this meta‐analysis was to summarize the results from existing evidence on the effect of Aronia consumption on lipid profile, blood pressure, and biomarkers of inflammation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of Aronia consumption on lipid profile, blood pressure, and biomarkers of inflammation: A systematic review and meta‐analysis of randomized controlled trials

Rahmani

Clark

Kord‐Varkaneh

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

Plant derivatives, such as anthocyanin-rich phytochemicals, have been reported to elicit a positive effect on lipid profile. Therefore, the aim of this study was to systematically review and meta-analyze the effects of Aronia consumption on lipid profiles, blood pressure, and biomarkers of inflammation in randomized controlled trials.A systematic search was performed in PubMed/MEDLINE, Cochrane, and SCOPUS up to December 2018. Seven studies were identified and analyzed in this metaanalysis. Our study found a significant increase in high-density lipoprotein (HDL; weighted mean difference [WMD]: 1.48 mg/dl, 95% confidence interval, CI, [1.29, 1.68]) and diastolic blood pressure (WMD: 2.55 mmHg, 95% CI [0.63, 4.47]) following Aronia consumption. There was no significant effect on systolic blood pressure and C-reactive protein, tumor necrosis factor, and interleukin-1. Furthermore, subgroup analysis showed that cholesterol (WMD: −7.18, 95% CI [−13.90, −0.46]) and lowdensity lipoprotein (LDL; WMD: −5.84, 95% CI [−6.91, −4.77]) decreased more significantly in interventions less than 10 weeks in duration. Dose-response analysis demonstrated a significant reduction in triglyceride levels when dose of Aronia was increased to 300 mg/day. In conclusion, the results demonstrated a significant increase in HDL and reduction in total cholesterol and LDL among patients supplementing with Aronia.

show abstract

Section: Discussionmentioning

confidence: 68%

Section: Introductionmentioning

confidence: 99%

The effect of Aronia consumption on lipid profile, blood pressure, and biomarkers of inflammation: A systematic review and meta‐analysis of randomized controlled trials

Rahmani

Clark

Kord‐Varkaneh

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…Further, A. melanocarpa berries, juice, and fruit extracts exhibit hypoglycemic effect in vitro and in vivo . A. melanocarpa juice reduced blood glucose levels in animal models of diabetes through the inhibition of α‐glucosidase and α‐amylase activities (Worsztynowicz, Napierała, Białas, Grajek, & Olkowicz, 2014; Yamane et al., 2016). Additionally, anthocyanins isolated from A. melanocarpa could scavenge excessive reactive oxygen species (ROS) generated as a result of high glucose levels in pancreatic β‐cells (Rugină et al., 2015).…”

Section: Introductionmentioning

confidence: 99%

Beneficial effects of Aronia melanocarpa berry extract on hepatic insulin resistance in type 2 diabetes mellitus rats

Xin

Zhang

et al. 2020

Journal of Food Science

View full text Add to dashboard Cite

We aimed to investigate) the effects of Aronia melanocarpa berry extract (AMBE) on hepatic insulin resistance and its mechanism at the molecular level in high-fat diet (HFD)-and streptozotocin (STZ)-induced type 2 diabetes mellitus (T2DM) rats. The rats were supplemented with AMBE at doses of 100 and 400 mg/kg body weight (bw) daily for 8 weeks. AMBE significantly reduced blood glucose and serum insulin levels and the homeostatic model assessment for insulin resistance score; improved glucose tolerance; increased hepatic glycogen content; and regulated glucose metabolism enzyme activity, including glucokinase, pyruvate kinase, phosphoenolpyruvate carboxykinase, and glucose-6-phosphatase in the liver. AMBE also reduced lipid accumulation and oxidative stress along with inflammation in the hepatic tissue of T2DM rats and improved hepatic function. The phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway was activated by AMBE through the elevation of insulin receptor substrate-2, PI3K, Akt, and glycogen synthase kinase-3β phosphorylation and glucose transporter 2, which might contribute to the promotion of glycogen synthesis and improvement of hepatic insulin resistance. AMBE shows promise as an ingredient of functional foods for alleviating hepatic insulin resistance in T2DM.Keywords: Aronia melanocarpa berry, hepatic insulin resistance, PI3K/Akt signaling pathway, type 2 diabetes mellitus Practical Application: The extract from the berries of Aronia melanocarpa (Michx.) Elliott (AMBE), with its relatively high content of polyphenolic compounds, has been shown to exert hypoglycemic effects in animal models of diabetes. Our findings support the use of A. melanocarpa as a functional food additive for the alleviation of hepatic insulin resistance and the management of glucose homeostasis in T2DM.

show abstract

“…For instance, it has been argued whether DPP‐IV must be or must not be administered to cancer patients with diabetes, whereas other studies support the oral administration of DPP‐IV inhibitors in order to either enhance tumor immunotherapy or to slow the growth of different tumors or to suppress colorectal cancer lung metastases in mice . Other studies have demonstrated their therapeutic effects on obesity, neuropathy, and hepatic and renal pathologies. Recent studies have also shown that it is possible to design DPP‐IV inhibitors with dual bioactivity on other targets involved in cardiovascular diseases like ACE or β‐adrenergic receptors …”

Section: Introductionmentioning

confidence: 99%

Activity and selectivity cliffs for DPP‐IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening

Ojeda-Montes

Gimeno

Tomás-Hernández

et al. 2018

Medicinal Research Reviews

View full text Add to dashboard Cite

The inhibition of dipeptidyl peptidase-IV (DPP-IV) has emerged over the last decade as one of the most effective treatments for type 2 diabetes mellitus, and consequently (a) 11 DPP-IV inhibitors have been on the market since 2006 (three in 2015), and (b) 74 noncovalent complexes involving human DPP-IV and drug-like inhibitors are available at the Protein Data Bank (PDB). The present review aims to (a) explain the most important activity cliffs for DPP-IV noncovalent inhibition according to the binding site structure of DPP-IV, (b) explain the most important selectivity cliffs for DPP-IV noncovalent inhibition in comparison with other related enzymes (i.e., DPP8 and DPP9), and (c) use the information deriving from this activity/selectivity cliff analysis to suggest how virtual screening protocols might be improved to favor the early identification of potent and selective DPP-IV inhibitors in molecular databases (because they have not succeeded in identifying selective DPP-IV inhibitors with IC ≤ 100 nM). All these goals are achieved with the help of available homology models for DPP8 and DPP9 and an analysis of the structure-activity studies used to develop the noncovalent inhibitors that form part of some of the complexes with human DPP-IV available at the PDB.

show abstract

Improvement of blood glucose levels and obesity in mice given aronia juice by inhibition of dipeptidyl peptidase IV and α-glucosidase

Cited by 44 publications

References 27 publications

The effect of Aronia consumption on lipid profile, blood pressure, and biomarkers of inflammation: A systematic review and meta‐analysis of randomized controlled trials

The effect of Aronia consumption on lipid profile, blood pressure, and biomarkers of inflammation: A systematic review and meta‐analysis of randomized controlled trials

Beneficial effects of Aronia melanocarpa berry extract on hepatic insulin resistance in type 2 diabetes mellitus rats

Activity and selectivity cliffs for DPP‐IV inhibitors: Lessons we can learn from SAR studies and their application to virtual screening

Contact Info

Product

Resources

About